Addendum

Sarilumab (polymyalgia rheumatica) – Addendum to Project A25-18

Report documents

Indication:

Adults with polymyalgia rheumatica who have had an inadequate response to corticosteroids or who experience a relapse during corticosteroid taper

Result of dossier assessment:

Patients for whom corticosteroids are the appropriate treatment of physician’s choice: hint of a non-quantifiable added benefit
Patients for whom the combination of corticosteroids with methotrexate is the appropriate treatment of physician’s choice: added benefit not proven

07-08-2025 A G-BA decision was published.
G-BA documents on this decision

Project no.: A25-83
Commission: Commission awarded on 24.06.2025 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Muscles, bones and joints
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI: https://doi.org/10.60584/A25-83_en

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.